Dermata Therapeutics Inc.

0.81
0.10 (13.51%)
At close: Apr 23, 2025, 3:59 PM
0.79
-2.05%
Pre-market: Apr 24, 2025, 08:09 AM EDT
13.51%
Bid 0.78
Market Cap 4.87M
Revenue (ttm) n/a
Net Income (ttm) -12.29M
EPS (ttm) -8.03
PE Ratio (ttm) -0.1
Forward PE -0.7
Analyst Buy
Ask 0.81
Volume 435,233
Avg. Volume (20D) 1,600,281
Open 0.71
Previous Close 0.71
Day's Range 0.71 - 0.85
52-Week Range 0.69 - 6.17
Beta 0.58

About DRMA

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phas...

Industry Biotechnology
Sector Healthcare
IPO Date Aug 13, 2021
Employees 8
Stock Exchange NASDAQ
Ticker Symbol DRMA
Full Company Profile

Analyst Forecast

According to 1 analyst ratings, the average rating for DRMA stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 643.31% from the latest price.

Stock Forecasts
3 weeks ago
+5.19%
Dermata shares are trading higher after the compan... Unlock content with Pro Subscription
4 months ago
+19.01%
Dermata Therapeutics shares are trading higher after the company received a notice of allowance for a U.S. patent titled "COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN CONDITIONS (INCLUDING ACNE)"